2308-PUB: Liraglutide 3 mg for Weight Loss in a Real-World Setting: Clinical Outcomes after 56 Weeks

Background: Liraglutide 3 mg was approved in the UAE for the treatment of obesity in residents with BMI >30 kg/m2 or BMI >27 kg/m2 with obesity-related complications and clinical use started in January 2017 at the Imperial College London Diabetes Centre (ICLDC). The proportions of participants achieving weight loss of ≥5%, ≥10% and ≥15% at 16 weeks were 60%, 23% and 6%. Methods: Retrospective review of clinical data from a cohort...